Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes

Cell Chemical Biology

Volumn 23, Issue 8, 2016, Pages 1023-1035

  Poreba, Marcin ^a,b   Solberg, Rigmor ^b,c   Rut, Wioletta ^a   Lunde, Ngoc Nguyen ^c   Kasperkiewicz, Paulina ^a   Snipas, Scott J ^b   Mihelic, Marko ^d   Turk, Dusan ^d   Turk, Boris ^d   Salvesen, Guy S ^b   Drag, Marcin ^a  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CASPASE; LEGUMAIN; PROTEINASE; CYSTEINE PROTEINASE; ENZYME INHIBITOR;

ARTICLE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; COUNTER SELECTION SUBSTRATE LIBRARY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYBRID COMBINATORIAL SUBSTRATE LIBRARY; MOLECULAR LIBRARY; MOLECULAR PROBE; CELL LINE; CHEMISTRY; COMBINATORIAL CHEMISTRY; CONFORMATION; METABOLISM; PH; PHARMACOLOGY; SYNTHESIS;

CELL LINE; COMBINATORIAL CHEMISTRY TECHNIQUES; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR CONFORMATION; MOLECULAR PROBES; SUBSTRATE SPECIFICITY;

EID: 84979753714     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2016.05.020     Document Type: Article

References (61)

1. Alvarez-Fernandez, M., Barrett, A.J., Gerhartz, B., Dando, P.M., Ni, J., Abrahamson, M., Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem. 274 (1999), 19195–19203.
2. Asgian, J.L., James, K.E., Li, Z.Z., Carter, W., Barrett, A.J., Mikolajczyk, J., Salvesen, G.S., Powers, J.C., Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J. Med. Chem. 45 (2002), 4958–4960.
3. Bajjuri, K.M., Liu, Y., Liu, C., Sinha, S.C., The legumaisn protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. ChemMedChem 6 (2011), 54–59.
4. Boatright, K.M., Renatus, M., Scott, F.L., Sperandio, S., Shin, H., Pedersen, I.M., Ricci, J.E., Edris, W.A., Sutherlin, D.P., Green, D.R., et al. A unified model for apical caspase activation. Mol. Cell 11 (2003), 529–541.
5. Briggs, J.J., Haugen, M.H., Johansen, H.T., Riker, A.I., Abrahamson, M., Fodstad, O., Maelandsmo, G.M., Solberg, R., Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer, 10, 2010, 17.
6. Chan, C.B., Abe, M., Hashimoto, N., Hao, C., Williams, I.R., Liu, X., Nakao, S., Yamamoto, A., Zheng, C., Henter, J.I., et al. Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. Proc. Natl. Acad. Sci. USA 106 (2009), 468–473.
7. Chen, J.M., Dando, P.M., Rawlings, N.D., Brown, M.A., Young, N.E., Stevens, R.A., Hewitt, E., Watts, C., Barrett, A.J., Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J. Biol. Chem. 272 (1997), 8090–8098.
8. Chen, J.M., Rawlings, N.D., Stevens, R.A., Barrett, A.J., Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett. 441 (1998), 361–365.
9. Chen, J.M., Fortunato, M., Barrett, A.J., Activation of human prolegumain by cleavage at a C-terminal asparagine residue. Biochem. J. 352 (2000), 327–334.
10. Chen, J.M., Fortunato, M., Stevens, R.A., Barrett, A.J., Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol. Chem. 382 (2001), 777–783.
11. Choi, S.J., Reddy, S.V., Devlin, R.D., Menaa, C., Chung, H., Boyce, B.F., Roodman, G.D., Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J. Biol. Chem. 274 (1999), 27747–27753.
12. Clerin, V., Shih, H.H., Deng, N., Hebert, G., Resmini, C., Shields, K.M., Feldman, J.L., Winkler, A., Albert, L., Maganti, V., et al. Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis 201 (2008), 53–66.
13. Dall, E., Brandstetter, H., Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68 (2012), 24–31.
14. Dall, E., Brandstetter, H., Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proc. Natl. Acad. Sci. USA 110 (2013), 10940–10945.
15. Dall, E., Brandstetter, H., Structure and function of legumain in health and disease. Biochimie 122 (2016), 126–150.
16. Denault, J.B., Eckelman, B.P., Shin, H., Pop, C., Salvesen, G.S., Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. Biochem. J. 405 (2007), 11–19.
17. Edgington, L.E., Verdoes, M., Ortega, A., Withana, N.P., Lee, J., Syed, S., Bachmann, M.H., Blum, G., Bogyo, M., Functional imaging of legumain in cancer using a new quenched activity-based probe. J. Am. Chem. Soc. 135 (2013), 174–182.
18. Ekici, O.D., Gotz, M.G., James, K.E., Li, Z.Z., Rukamp, B.J., Asgian, J.L., Caffrey, C.R., Hansell, E., Dvorak, J., McKerrow, J.H., et al. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J. Med. Chem. 47 (2004), 1889–1892.
19. Garcia-Calvo, M., Peterson, E.P., Rasper, D.M., Vaillancourt, J.P., Zamboni, R., Nicholson, D.W., Thornberry, N.A., Purification and catalytic properties of human caspase family members. Cell Death Differ. 6 (1999), 362–369.
20. Gawenda, J., Traub, F., Luck, H.J., Kreipe, H., von Wasielewski, R., Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res. Treat. 102 (2007), 1–6.
21. Gotz, M.G., James, K.E., Hansell, E., Dvorak, J., Seshaadri, A., Sojka, D., Kopacek, P., McKerrow, J.H., Caffrey, C.R., Powers, J.C., Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J. Med. Chem. 51 (2008), 2816–2832.
22. Hashimoto, S., Suzuki, T., Dong, H.Y., Yamazaki, N., Matsushima, K., Serial analysis of gene expression in human monocytes and macrophages. Blood 94 (1999), 837–844.
23. Haugen, M.H., Johansen, H.T., Pettersen, S.J., Solberg, R., Brix, K., Flatmark, K., Maelandsmo, G.M., Nuclear legumain activity in colorectal cancer. PLoS One, 8, 2013, e52980.
24. James, K.E., Gotz, M.G., Caffrey, C.R., Hansell, E., Carter, W., Barrett, A.J., McKerrow, J.H., Powers, J.C., Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases). Biol. Chem. 384 (2003), 1613–1618.
25. Johansen, H.T., Knight, C.G., Barrett, A.J., Colorimetric and fluorimetric microplate assays for legumain and a staining reaction for detection of the enzyme after electrophoresis. Anal. Biochem. 273 (1999), 278–283.
26. Kasperkiewicz, P., Poreba, M., Snipas, S.J., Parker, H., Winterbourn, C.C., Salvesen, G.S., Drag, M., Design of ultrasensitive probes for human neutrophil elastase through hybrid combinatorial substrate library profiling. Proc. Natl. Acad. Sci. USA 111 (2014), 2518–2523.
27. Kato, D., Boatright, K.M., Berger, A.B., Nazif, T., Blum, G., Ryan, C., Chehade, K.A., Salvesen, G.S., Bogyo, M., Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1 (2005), 33–38.
28. Kembhavi, A.A., Buttle, D.J., Knight, C.G., Barrett, A.J., The two cysteine endopeptidases of legume seeds: purification and characterization by use of specific fluorometric assays. Arch. Biochem. Biophys. 303 (1993), 208–213.
29. Lecaille, F., Muno, D., Kominami, E., Ishidoh, K., Proteinases participating in the processing and activation of prolegumain in primary cultured rat macrophages. Biol. Chem. 385 (2004), 511–516.
30. Lee, J., Bogyo, M., Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain. ACS Chem. Biol. 5 (2010), 233–243.
31. Lee, J., Bogyo, M., Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain. Bioorg. Med. Chem. Lett. 22 (2012), 1340–1343.
32. Li, N., Liu, Q., Su, Q., Wei, C., Lan, B., Wang, J., Bao, G., Yan, F., Yu, Y., Peng, B., et al. Effects of legumain as a potential prognostic factor on gastric cancers. Med. Oncol., 30, 2013, 621.
33. Liu, C., Sun, C., Huang, H., Janda, K., Edgington, T., Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63 (2003), 2957–2964.
34. Loak, K., Li, D.N., Manoury, B., Billson, J., Morton, F., Hewitt, E., Watts, C., Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase. Biol. Chem. 384 (2003), 1239–1246.
35. Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Lee, S.H., Dolman, C., Markowitz, D., Wu, W., Liu, C., Reisfeld, R.A., et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116 (2006), 2132–2141.
36. Manoury, B., Mazzeo, D., Li, D.N., Billson, J., Loak, K., Benaroch, P., Watts, C., Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. Immunity 18 (2003), 489–498.
37. Mathieu, M.A., Bogyo, M., Caffrey, C.R., Choe, Y., Lee, J., Chapman, H., Sajid, M., Craik, C.S., McKerrow, J.H., Substrate specificity of schistosome versus human legumain determined by P1-P3 peptide libraries. Mol. Biochem. Parasitol. 121 (2002), 99–105.
38. Mattock, K.L., Gough, P.J., Humphries, J., Burnand, K., Patel, L., Suckling, K.E., Cuello, F., Watts, C., Gautel, M., Avkiran, M., et al. Legumain and cathepsin-L expression in human unstable carotid plaque. Atherosclerosis 208 (2010), 83–89.
39. McLuskey, K., Mottram, J.C., Comparative structural analysis of the caspase family with other clan CD cysteine peptidases. Biochem. J. 466 (2015), 219–232.
40. Miller, G., Matthews, S.P., Reinheckel, T., Fleming, S., Watts, C., Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 25 (2011), 1606–1617.
41. Morita, Y., Araki, H., Sugimoto, T., Takeuchi, K., Yamane, T., Maeda, T., Yamamoto, Y., Nishi, K., Asano, M., Shirahama-Noda, K., et al. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett. 581 (2007), 1417–1424.
42. Niestroj, A.J., Feussner, K., Heiser, U., Dando, P.M., Barrett, A., Gerhartz, B., Demuth, H.U., Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones. Biol. Chem. 383 (2002), 1205–1214.
43. Ohno, Y., Nakashima, J., Izumi, M., Ohori, M., Hashimoto, T., Tachibana, M., Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness. World J. Urol. 31 (2013), 359–364.
44. Ovat, A., Muindi, F., Fagan, C., Brouner, M., Hansell, E., Dvorak, J., Sojka, D., Kopacek, P., McKerrow, J.H., Caffrey, C.R., et al. Aza-peptidyl Michael acceptor and epoxide inhibitors—potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J. Med. Chem. 52 (2009), 7192–7210.
45. Poreba, M., Drag, M., Current strategies for probing substrate specificity of proteases. Curr. Med. Chem. 17 (2010), 3968–3995.
46. Poreba, M., Kasperkiewicz, P., Snipas, S.J., Fasci, D., Salvesen, G.S., Drag, M., Unnatural amino acids increase sensitivity and provide for the design of highly selective caspase substrates. Cell Death Differ. 21 (2014), 1482–1492.
47. Poreba, M., Szalek, A., Kasperkiewicz, P., Drag, M., Positional scanning substrate combinatorial library (PS-SCL) approach to define caspase substrate specificity. Methods Mol. Biol. 1133 (2014), 41–59.
48. Powers, J.C., Asgian, J.L., Ekici, O.D., James, K.E., Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102 (2002), 4639–4750.
49. Qiu, J., Ai, L., Ramachandran, C., Yao, B., Gopalakrishnan, S., Fields, C.R., Delmas, A.L., Dyer, L.M., Melnick, S.J., Yachnis, A.T., et al. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab. Invest. 88 (2008), 910–925.
50. Rawlings, N.D., Barrett, A.J., Bateman, A., Using the MEROPS database for proteolytic enzymes and their inhibitors and substrates. Curr. Protoc. Bioinformatics 48 (2014), 1.25.1–1.25.33.
51. Rozman-Pungercar, J., Kopitar-Jerala, N., Bogyo, M., Turk, D., Vasiljeva, O., Stefe, I., Vandenabeele, P., Bromme, D., Puizdar, V., Fonovic, M., et al. Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ. 10 (2003), 881–888.
52. Sadaghiani, A.M., Verhelst, S.H., Bogyo, M., Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 11 (2007), 20–28.
53. Salvesen, G.S., Nagase, H., Inhibition of proteolytic enzymes. Bonf, J.S., Beynon, R.J., (eds.) Proteolytic Enzymes: A Practical Approach, Second Edition, 2001, Oxford University Press, Oxford, 105–130.
54. Schwarz, G., Brandenburg, J., Reich, M., Burster, T., Driessen, C., Kalbacher, H., Characterization of legumain. Biol. Chem. 383 (2002), 1813–1816.
55. Sexton, K.B., Witte, M.D., Blum, G., Bogyo, M., Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain. Bioorg. Med. Chem. Lett. 17 (2007), 649–653.
56. Shirahama-Noda, K., Yamamoto, A., Sugihara, K., Hashimoto, N., Asano, M., Nishimura, M., Hara-Nishimura, I., Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J. Biol. Chem. 278 (2003), 33194–33199.
57. Smith, R., Johansen, H.T., Nilsen, H., Haugen, M.H., Pettersen, S.J., Maelandsmo, G.M., Abrahamson, M., Solberg, R., Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Biochimie 94 (2012), 2590–2599.
58. Snipas, S.J., Stennicke, H.R., Riedl, S., Potempa, J., Travis, J., Barrett, A.J., Salvesen, G.S., Inhibition of distant caspase homologues by natural caspase inhibitors. Biochem. J. 357 (2001), 575–580.
59. Stennicke, H.R., Salvesen, G.S., Biochemical characteristics of caspases-3, -6, -7, and -8. J. Biol. Chem. 272 (1997), 25719–25723.
60. Stennicke, H.R., Salvesen, G.S., Caspases: preparation and characterization. Methods 17 (1999), 313–319.
61. Wang, L., Chen, S., Zhang, M., Li, N., Chen, Y., Su, W., Liu, Y., Lu, D., Li, S., Yang, Y., et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J. Cell Biochem. 113 (2012), 2679–2686.